TTRX
Turn Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.85
+0.15 (+4.05%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.41M | 28.26M | 24.54M |
| Net Income | 5.07M | 4.33M | 4.07M |
| EPS | — | — | — |
| Profit Margin | 17.8% | 15.3% | 16.6% |
| Rev Growth | +18.7% | -2.9% | -7.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 52.60M | 49.37M | 49.93M |
| Total Equity | 73.19M | 64.37M | 61.81M |
| D/E Ratio | 0.72 | 0.77 | 0.81 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.12M | 6.76M | 5.89M |
| Free Cash Flow | 5.68M | 5.26M | 4.99M |